Return to Listing

1 result(s) for Carboxyamidotriazole Orotate (CTO)

PI Name Protocol # Title
Matthew Taylor IRB00006867 A Phase 1 Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients with Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy with TemodarĀ® in Patients with Glioblastom Multiforme
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080

You may qualify for additional trials within our Phase 1 Program